Business
India
Can Symbiotec Pharmalab IPO deliver long-term growth for high-risk investors?
Symbiotec Pharmalab plans a ₹150 crore IPO to repay debt and expand operations. The company holds a global leadership position in corticosteroid and…
Bloomberg
BBC Sport
The Hindu
India Today - India
Al Jazeera - World
ESPN Cricket Info